Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial: ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY

NCT06409910 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06409910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06409910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial: ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
November 26, 2024
Completion date
November 30, 2030
Enrollment
204 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

post-operative prostate cancer